The breast implant is made up of a soft silicone shell called an implant and is filled with a gel or a saltwater solution. Breast implants are used for breast augmentation, which is surgery to increase breast size. This surgery involves placing breast implants under the breast tissue or chest muscles. A breast implant is a prosthesis used to change the shape, size, and contour of a person's breast. Breast implants are ideally used for breast augmentation which refers to as augmentation mammoplasty. Breast implants are medical devices that are used to augment the size of the breasts, either for cosmetic or reconstruction purposes, following mastectomy or to correct a congenital abnormality. Breast implants can be either round shaped or teardrop/anatomical shaped. Round breast implants are the most commonly used breast implants and are highly preferred among women during breast augmentation procedures. Teardrop breast implants, also known as contoured implants, are designed to maintain their shape with a sloped contoured that fills out more at the bottom than at the top giving the natural shape of the breasts. The breast implant surgery also has some adverse events associated with it, some of the adverse events are mentioned here as follows infection, rupture, rashes, skin changes, breast pain, cosmetic changes to the breasts such as hardness and asymmetry, and a fluid collection around the breast. The breast augmentation or augmentation mammoplasty procedure for the placement of breast implant devices has three purposes:

• primary reconstruction: the replacement of breast tissues damaged by trauma (blunt, penetrating, blast), disease (breast cancer), and failed anatomic development (tuberous breast deformity)
• Reconstruction and revision: to revise (recorrect) the outcome of a previous breast reconstruction surgery
• primary augmentation: to aesthetically augment the form, size, and feel of the breasts

Market Dynamics

An increase in focus on improving long-term safety and quality of life is likey to boost the growth of market over the forecast period. For instance, in August 2022, BellaSeno GmbH, ISO 13485-certified medical technology company, announced the initiation of the two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia. The initial experiment is anticipated to include 10 individuals with pectus excavatum, a typical congenital chest wall abnormality in which the breastbone is recessed into the chest. Dr. Michael Wagels, a senior lecturer at the University of Queensland, Specialist Plastic and Reconstructive Surgeon at Princess Alexandra Hospital, Director of the Australian Centre for Complex Integrated Surgical Solutions (ACCISS), and Director of the Herston Biofabrication Institute (HBI), is the trial's principal investigator. The second trial intends to enlist 20 individuals who either require surgery for congenital breast abnormalities or breast implant revision. Prof. Owen Ung, Director of the Comprehensive Breast Cancer Institute (CBCI), Consultant Breast Surgeon at the Royal Brisbane and Women's Hospital, and Professor of Surgery at the University of Queensland in Australia, is the principal investigator of the second trial.

Key features of the study:

• This report provides an in-depth analysis of the Asia Pacific breast implants market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

• It profiles key players in the Asia Pacific breast implants market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Allergan, Plc. (AbbVie Inc.), Mentor Worldwide LLC, GC Aesthetics Plc, Sientra, Inc., POLYTECH Health and Aesthetics GmBH, Establishment Labs S.A., Laboratories Arion, HanSBiomed Co. Ltd., Groupe Sebbin SAS, and GG Biotechnology Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Asia Pacific breast implants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia Pacific breast implants market

Detailed Segmentation:

• Asia Pacific Breast Implants Market, By Product Type:
  • Silicone Breast Implant
  • Saline Breast Implant
• Asia Pacific Breast Implants Market, By Shape:
  • Round Breast Implant
  • Anatomical Breast Implant
• Asia Pacific Breast Implants Market, By Application:
  • Cosmetic Surgery
  • Reconstructive Surgery
• Asia Pacific Breast Implants Market, By End User:
  • Hospitals
  • Cosmetic Clinics
• Asia Pacific Breast Implants Market, By Country:
  • China
  • India
  • Japan  
  • Australia
  • South Korea
  • ASEAN
  • Rest of APAC   
• Company Profiles
  • Allergan, Plc. (AbbVie Inc.)*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Mentor Worldwide LLC
  • GC Aesthetics Plc
  • Sientra, Inc.
  • POLYTECH Health and Aesthetics GmBH
  • Establishment Labs S.A.
  • Laboratories Arion
  • HanSBiomed Co. Ltd.
  • Groupe Sebbin SAS
  • GG Biotechnology Ltd

“*” marked represents similar segmentation in other categories in the respective section.